Specifically, the challenges in Alzheimer’s disease (AD) trials, where the failure of several β-secretase 1 (BACE1) inhibitors [55] demonstrates the risk of targeting a surrogate biomarker too late in the disease course, underscoring the necessity of early intervention in FTD. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.